Table 1.
Summary of Baseline Demographics and Other Characteristics of the PK Analysis Data Set (n = 368)
| Continuous Covariates | Units | Median (Range) |
|---|---|---|
| Body weight | kg | 79.0 (43.0‐130) |
| BMI | kg/m2 | 28.1 (18.4‐37.0) |
| Age | y | 53.0 (18.0‐75.0) |
| Albumin | g/L | 45.0 (37.0‐54.0) |
| ALT | U/L | 19.0 (7.00‐117) |
| Bilirubin | μmol/L | 7.00 (1.50‐35.0) |
| sST2 | ng/mL | 11.7 (1.56‐222) |
| eGFR | mL/min/1.73 m2 | 87.9 (29.3‐161) |
| Eosinophils | cells/μL | 180 (5.00‐1930) |
| Categorical covariates | N (%) | |
| Dose | ||
| 70 mg every 4 wks | 124 (33.7) | |
| 210 mg every 4 wks | 124 (33.7) | |
| 490 mg every 4 wks | 120 (32.6) | |
| Sex | ||
| Male | 122 (33.2) | |
| Female | 246 (66.8) | |
| Race | ||
| Asian | 17 (4.6) | |
| Black | 20 (5.4) | |
| Native American | 17 (4.6) | |
| Multiple | 5 (1.4) | |
| White | 309 (84.0) | |
| Subject‐level ADA status a | ||
| Negative | 341 (92.7) | |
| Positive | 27 (7.3) |
ADA, antidrug antibody; ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; PK, pharmacokinetic; sST2, soluble ST2; wks, weeks.
a
Patients are considered to be ADA positive if they had either treatment‐induced ADA or treatment‐enhanced ADA; otherwise, they were considered to be ADA negative.